DrugBank

MAY 22, 2024

Molecular dynamics (MD) simulations and other computational methods are vital tools in our arsenal , helping us peek into the atomic-level interactions and movements within the protein, helping reveal potential new binding sites induced by small molecule interactions. DNA and RNA are also key players, each bringing unique challenges.

Small Molecule 67

Small Molecule RNA DNA Pharmaceutical Companies 67

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. Multifunctional Small Molecules and Peptides Beyond PROTACs, there are other exciting tools in the new drug discovery toolbox.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

DrugBank

MAY 15, 2024

Researchers are experimenting with biologics—larger biological molecules that can do things small molecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells. Understanding why these targets are resistant to current therapeutic strategies is crucial.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. The novel, hairpin-shaped molecule was named cabRNA for CBASS-activating bacteriophage RNA.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Drug Discovery World

DECEMBER 21, 2023

Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker. Read the article: Where are the hottest drug discovery hubs in the US?

FDA Approval 147

FDA Approval Therapies Small Molecule Clinical Trials 147

Covalent Modifiers

AUGUST 14, 2023

For both cancer and healthy genomes, we find that cysteine acquisition is a ubiquitous consequence of genetic variation that is further elevated in the context of decreased DNA repair.

Small Molecule 52

Small Molecule RNA DNA Therapies 52

Drug Discovery World

JULY 8, 2024

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. However, the RNA landscape has drastically changed in recent years and we now know that the molecule is more than just a transient, linear carrier of information.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Dark Matter Blog

APRIL 4, 2023

Prior to 2015, I had a casual relationship, at best, with targeting RNA. The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. Welcome to the RNA world. Familiar tools to solve familiar problems with proteins.

Small Molecule 52

Small Molecule RNA Fragment Screening DNA 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Sygnature Discovery

JUNE 17, 2024

Diverse Target Classes We Work With: Soluble Proteins: This includes kinases, ligases, transcription factors, helicases, polymerases, and DNA/RNA modifying enzymes, among others. Membrane Proteins: Examples include cell surface receptors, GPCRs, and transporters. Nucleic Acid Targets: Focusing on specific interactions and functions.

Biophysical Assays 52

Biophysical Assays Screening Hits Fragment Screening Assay Development 52

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Artificial intelligence. Wu Z, et al.

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

The Pharma Data

MARCH 7, 2022

The new technique controls gene activity without altering the DNA sequence of the genome by targeting chemical modifications that help package genes in our chromosomes and regulate their activity. Cas9 binds and uses RNA as an address-tag. The AI-designed blocking protein was the cargo of the dCas9-RNA construct.

RNA 52

RNA DNA Packaging Small Molecule 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Science 100

Science Drugs FDA Engineering 100

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. It has a vibrant community of life-science companies, from global pharma to smaller start-ups.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA). The benefits of mRNA mRNA-based therapies have multiple benefits over existing DNA and protein platforms.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Dark Matter Blog

AUGUST 31, 2020

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52

RNA Small Molecule Bioinformatics Computational Chemistry 52

Drug Discovery World

SEPTEMBER 6, 2022

The fact that these benefits “may not be attainable with small molecules or even simpler biologics, as well as long periods of market exclusivity,” Scharenberg says, means that “more complicated compounds are harder to copy and require more investment to compete with making them strong continued investment targets.” .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Codon

JUNE 11, 2024

And unlike traditional DNA sequencers, which parse genetic material by breaking it up into fragments and interpreting it chunk-by-chunk, a nanopore device unspools a long strand of DNA and reads it all at once. A scientist can isolate DNA and load up a flow cell in fifteen minutes. Nanopore devices work incredibly fast.

DNA 77

DNA Engineering RNA Small Molecule 77

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 246

DNA Engineering Drugs Vaccine 246

Codon

AUGUST 27, 2024

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Reading DNA The first step in detecting a novel pathogen is recognizing it as an anomaly amidst a noisy background of other material. After copying the DNA to form a big pool, each piece is sequenced.

DNA 90

DNA Hospitals Laboratories Virus 90

Sygnature Discovery

JUNE 17, 2024

Our in-house SPR equipment comprises: 2x Biacore TM 8K+ 3x Biacore TM 8K 1x Biacore TM T200 This covers mM binders, such as fragments, through to sub pM interactions (such as late stage small molecules or very high affinity biological interactions, Tollenaere et al 2023 [link] ). This technology measures affinities from mM to nM.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52

Drug Discovery World

JUNE 6, 2023

However, what he found particularly interesting at the meeting is the emergence of more small molecule immune oncology agents that are actually starting to look as though they might work. ” Meet the exhibitor At AACR, Integrated DNA Technologies (IDT) announced the launch of a new core solid tumour panel for cancer research.

Small Molecule 130

Small Molecule DNA RNA Research 130

Codon

FEBRUARY 28, 2023

1 One rarely pauses to ponder how so much DNA — let alone sugar, proteins, and everything else — can fit inside such a small vessel. Biochemistry textbooks depict cells as spacious places, where molecules float in secluded harmony. How fast does DNA become RNA, or RNA protein? A typical E.

RNA 52

RNA DNA Cell Biology Small Molecule 52

Drug Discovery World

FEBRUARY 29, 2024

In the first article, Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside.

Small Molecule 130

Small Molecule DNA Therapies Production 130

Codon

APRIL 2, 2023

But now, by studying DNA extracted from microbes in the blood of almost 10,000 healthy people, this paper shows that there is no such thing. Read Transcription factors bind to DNA and control gene expression. Read Switchable hydrophobic pockets in DNA protocells enhance chemical conversion. Nature Microbiology. Meeussen J.V.W.

DNA 52

DNA RNA Engineering Licensing 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. The vaccine printer can make lots of different types of vaccines, including protein, DNA, and mRNA ones, but I’m sure this is all quite expensive right now. From Zhang et al.

Vaccine 52

Vaccine Engineering DNA RNA 52

Drug Discovery World

OCTOBER 17, 2023

A good example of this is recent work from the labs of Martin Guilliams and Charlotte Scott, who used spatial protein and RNA readouts to generate an unprecedented atlas of human and mouse livers and were able to characterise the hepatic macrophages induced in fatty liver diseases1.

Disease 130

Disease Small Molecule Drugs RNA 130

Codon

MARCH 20, 2023

Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Marine biofilm engineered to produce current in response to small molecules. Digital nanoreactors to control absolute stoichiometry and spatiotemporal behavior of DNA receptors within lipid bilayers.

Virus 52

Virus Engineering RNA Small Molecule 52

Codon

MAY 30, 2023

This week: A way to measure a transgene’s expression in the brain using ultrasound, a DNA sequencing method that uses 1000x less reagents, and base editors get even smaller. An engineered version of this protein can convert DNA bases with efficiencies up to 92%. so this Digest will be published more irregularly.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

This week: A way to measure a transgene’s expression in the brain using ultrasound, a DNA sequencing method that uses 1000x less reagents, and base editors get even smaller. An engineered version of this protein can convert DNA bases with efficiencies up to 92%. so this Digest will be published more irregularly.

DNA 52

DNA RNA Engineering Vaccine 52

Elrig

APRIL 29, 2024

She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. There, I supported AI-enabled DD efforts in their small molecule portfolio.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

The Pharma Data

AUGUST 3, 2021

The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. Business Development/Other Developments. The company announced the acquisition of Protomer Technologies Inc.,

Production 52

Production Marketing Research Government 52

KIF1A

AUGUST 20, 2024

Susannah is being treated with an Antisense Oligonucleotide (ASO) : To break down the term, this is a molecule designed with a sequence of 20 (oligo, “few”) letters of DNA (nucleotide) that match a sequence on the mutant KIF1A RNA (Antisense) and knock it down.

Science 52

Science Treatment Therapies Small Molecule 52

Alta Sciences

APRIL 17, 2024

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

DECEMBER 27, 2020

Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. STP705 is a small interfering RNA (siRNA) therapy that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-beta1 and COX-2 gene expression.

Clinical Trials 52

Clinical Trials Trials Therapies RNA 52

Drug Discovery World

NOVEMBER 13, 2023

Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’. Jana Langhoff, Tecan, on: ‘Opportunities and challenges of automating high throughput protein purification’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147